Browse the corpus

Aminocaproic acid, an antifibrinolytic agent, is approved by the U.S. Food and Drug Administration (FDA) for managing and treating acute bleeding disorders resulting from elevated fibrinolytic activity. This drug is indicated for the therapeutic management of acute hemorrhages leading to complications after cardiac surgery, hematological disorders, hepatic cirrhosis, neoplastic disease, congenital amegakaryocytic thrombocytopenia, and life-threatening bleeding conditions associated with abruptio placenta. This activity comprehensively reviews the indications, mechanism of action, and contraindications for aminocaproic acid in managing hyperfibrinolysis-induced hemorrhage. In addition, this review will highlight other critical factors, including the adverse event profile, off-label indications, dosing, and monitoring, essential for healthcare team members for treating patients with acute hyperfibrinolysis-induced hemorrhage and related conditions. Objectives: Identify appropriate indications for aminocaproic acid therapy in managing acute bleeding disorders associated with elevated fibrinolytic activity. Screen patients thoroughly to assess their suitability for aminocaproic acid therapy, considering contraindications and potential drug interactions. Implement proper dosing and administration of aminocaproic acid based on individual patient factors, such as age, weight, and medical history, to achieve optimal therapeutic outcomes. Assess patients regularly for potential adverse effects and monitor relevant parameters, including serum creatinine, blood urea nitrogen, and coagulation tests during aminocaproic acid therapy. Access free multiple choice questions on this topic.

Aminocaproic acid is associated with a low acute toxicity risk. Research on teratogenic in vitro studies has revealed no fetal abnormalities when administering aminocaproic acid dosages up to 5000 mcg/kg/d. Retinal changes have been reported in dogs after receiving aminocaproic acid orally over 1 year at doses approximately 7 times higher than the maximum recommended dose for in vivo use. A significant concern regarding aminocaproic acid treatment is whether this drug can increase patients' risk of thrombosis and intravascular coagulation. Although there are isolated reports of arterial or venous thrombosis, it is noteworthy that the underlying thrombotic comorbidity is present in each reported case.[17] Some cases of acute overdose of aminocaproic acid administered IV have been documented. The toxicities of such overdoses range from transient hypotension to severe and potentially fatal acute kidney injury. A patient with a history of seizures and brain tumors experienced seizures after receiving an 8-gram bolus IV injection of aminocaproic acid. In some cases, patients have experienced acute kidney injury after taking a 12-gram dose of aminocaproic acid. However, in other instances, patients have shown no signs of seizures and could tolerate doses as high as 100 grams. No specific antidote is available for use in the event of aminocaproic acid toxicity. However, case reports have described using tissue plasminogen activators for suspected antifibrinolytic-induced intraoperative thromboembolic events.[36] No established treatment for aminocaproic acid overdosage currently exists. Some evidence suggests that aminocaproic acid can be eliminated through hemodialysis or peritoneal dialysis. Total body clearance of aminocaproic acid is significantly decreased in patients with severe renal failure. In case of an overdose, it is advised to call the local poison center for current information and guidance.

When tissues are injured due to trauma, surgery, ischemia and reperfusion, or blood contact with large nonendothelial surfaces, it may lead to excessive fibrinolysis, resulting in bleeding, coagulopathies, and inflammatory responses. Numerous studies have shown that antifibrinolytic agents effectively reduce bleeding, blood transfusions, and adverse clinical outcomes. Aminocaproic acid is a medication used to treat acute bleeding disorders as an antifibrinolytic agent. The prophylactic use of aminocaproic acid, the synthetic lysine-analog antifibrinolytic agent, has been the primary pharmacological approach for blood conservation during cardiac surgery since aprotinin was discontinued from clinical use.[37] In the 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines, antifibrinolytic agents were strongly recommended as a crucial component of the blood conservation approach.[38] Aminocaproic acid is an effective treatment for reducing bleeding and chest tube drainage output in cardiac surgical patients. It has been found to have a well-tolerated adverse effect profile. Managing life-threatening hemorrhagic events requires a collaborative interprofessional team of healthcare professionals, including physicians from various specialties, advanced practice practitioners, nurses, laboratory technologists, and pharmacists. The morbidity and mortality associated with massive bleeding are significant without appropriate management. Uncontrolled bleeding during the perioperative period can lead to unavoidable consequences, such as re-operation, increased transfusion requirements, and multiorgan dysfunction.[3] When a clinician prescribes aminocaproic acid to patients, the pharmacist needs to verify the correct dosage and conduct medication reconciliation. The nursing staff should verify the administration and counsel patients on the drug's potential adverse effects and benefits. Promoting interprofessional care coordination with shared decision-making and open communication among healthcare providers would improve patient outcomes and reduce adverse events associated with aminocaproic acid therapy.